Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model

References

• Hodi, FS, O'Day, SJ, McDermott, DF, Weber, RW, Sosman, JA, Haanen, JB, Gonzalez, R, Robert, C, Schadendorf, D, Hassel, JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010;363:711–23. doi:10.1056/NEJMoa1003466. PMID:20525992.
   PubMed Web of Science ®Google Scholar
• Topalian, S, Hodi, F. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. Engl. J. 2012;366:2443–54. doi:10.1056/NEJMoa1200690.
   Google Scholar
• Brahmer, JR, Tykodi, SS, Chow, LQ, Hwu, WJ, Topalian, SL, Hwu, P, Drake, CG, Camacho, LH, Kauh, J, Odunsi, K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012;366:2455–65. doi:10.1056/NEJMoa1200694. PMID:22658128.
   PubMed Web of Science ®Google Scholar
• Rosenberg, SA, Dudley, ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 2004;101(Suppl):14639–45. doi:10.1073/pnas.0405730101. PMID:15381769.
   PubMedGoogle Scholar
• Ellebaek, E, Iversen, TZ, Junker, N, Donia, M, Engell-Noerregaard, L, Met, Ö, Hölmich, LR, Andersen, RS, Hadrup, SR, Andersen, MH, et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J. Transl. Med. 2012;10:169. doi:10.1186/1479-5876-10-169. PMID:22909342.
   PubMed Web of Science ®Google Scholar
• Andersen, R, Donia, M, Ellebaek, E, Borch, TH, Kongsted, P, Iversen, TZ, Hölmich, LR, Hendel, HW, Met, Ö, Andersen, MH, et al. Long-Lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated il2 regimen. Clin. Cancer Res. 2016;22:3734–45. doi:10.1158/1078-0432.CCR-15-1879. PMID:27006492.
   PubMed Web of Science ®Google Scholar
• Weiss, SA, Han, SW, Lui, K, Tchack, J, Shapiro, R, Berman, R, Zhong, J, Krogsgaard, M, Osman, I, Darvishian, F. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma. Hum. Pathol. 2016;57:116–25. doi:10.1016/j.humpath.2016.07.008. PMID:27473267.
   PubMed Web of Science ®Google Scholar
• Galon, J, Costes, A, Sanchez-Cabo, F, Kirilovsky, A, Mlecnik, B, Lagorce-Pagès, C, Tosolini, M, Camus, M, Berger, A, Wind, P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4. doi:10.1126/science.1129139. PMID:17008531.
   PubMed Web of Science ®Google Scholar
• Zhang, L, Conejo-Garcia, JR, Katsaros, D, Gimotty, PA, Massobrio, M, Regnani, G, Makrigiannakis, A, Gray, H, Schlienger, K, Liebman, MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003;348:203–13. doi:10.1056/NEJMoa020177. PMID:12529460.
   PubMed Web of Science ®Google Scholar
• Denkert, C, Wienert, S, Poterie, A, Loibl, S, Budczies, J, Badve, S, Bago-Horvath, Z, Bane, A, Bedri, S, Brock, J, et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod. Pathol. 2016;29:1155–64. doi:10.1038/modpathol.2016.109. PMID:27363491.
   PubMed Web of Science ®Google Scholar
• Fridman, WH, Pagès, F, Sautès-Fridman, C, Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer. 2012;12:298–306. doi:10.1038/nrc3245. PMID:22419253.
   PubMed Web of Science ®Google Scholar
• Tumeh, PC, Harview, CL, Yearley, JH, Shintaku, IP, Taylor, EJ, Robert, L, Chmielowski, B, Spasic, M, Henry, G, Ciobanu, V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71. doi:10.1038/nature13954. PMID:25428505.
   PubMed Web of Science ®Google Scholar
• Verdegaal, EME, de Miranda, NF, Visser, M, Harryvan, T, van Buuren, MM, Andersen, RS, Hadrup, SR, van der Minne, CE, Schotte, R, Spits, H, et al. Neoantigen landscape dynamics during human melanoma–T cell interactions. Nature. 2016;536:91–95. doi:10.1038/nature18945. PMID:27350335.
   PubMed Web of Science ®Google Scholar
• Pockaj, BA, Sherry, RM, Wei, JP, Yannelli, JR, Carter, CS, Leitman, SF, Carasquillo, JA, Steinberg, SM, Rosenberg, SA, Yang, JC. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer. 1994;73:1731–7. doi:10.1002/1097-0142(19940315)73:6%3c1731::AID-CNCR2820730630%3e3.0.CO;2-H. PMID:8156501.
   PubMed Web of Science ®Google Scholar
• Fisher, B, Packard, BS, Read, EJ, Carrasquillo, JA, Carter, CS, Topalian, SL, Yang, JC, Yolles, P, Larson, SM, Rosenberg, SA. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J. Clin. Oncol. 1989;7:250–61. doi:10.1200/JCO.1989.7.2.250. PMID:2644399.
   PubMed Web of Science ®Google Scholar
• Zlotnik, A, Burkhardt, AM, Homey, B. Homeostatic chemokine receptors and organ-specific metastasis. Nat. Rev. Immunol. 2011;11:597–606. doi:10.1038/nri3049. PMID:21866172.
   PubMed Web of Science ®Google Scholar
• Griffith, JW, Sokol, CL, Luster, AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu. Rev. Immunol. 2014;32:659–702. doi:10.1146/annurev-immunol-032713-120145. PMID:24655300.
   PubMed Web of Science ®Google Scholar
• Harlin, H, Meng, Y, Peterson, AC, Zha, Y, Tretiakova, M, Slingluff, C, McKee, M, Gajewski, TF. Chemokine expression in melanoma metastases associated with CD8 + T-CeII recruitment. Cancer Res. 2009;69:3077–85. doi:10.1158/0008-5472.CAN-08-2281. PMID:19293190.
   PubMed Web of Science ®Google Scholar
• Klarquist, J, Tobin, K, Farhangi Oskuei, P, Henning, SW, Fernandez, MF, Dellacecca, ER, Navarro, FC, Eby, JM, Chatterjee, S, Mehrotra, S, et al. Ccl22 diverts T regulatory cells and controls the growth of melanoma. Cancer Res. 2016;76:6230–40. doi:10.1158/0008-5472.CAN-16-0618. PMID:27634754.
   PubMed Web of Science ®Google Scholar
• Chow, MT, Luster, AD. Chemokines in Cancer. Cancer Immunol. Res. 2014;2:1125–31. doi:10.1158/2326-6066.CIR-14-0160. PMID:25480554.
   PubMed Web of Science ®Google Scholar
• Tran, KQ, Zhou, J, Durflinger, KH, Langhan, MM, Shelton, TE, Wunderlich, JR, Robbins, PF, Rosenberg, SA, Dudley, ME. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J. Immunother. 2008;31:742–51. doi:10.1097/CJI.0b013e31818403d5. PMID:18779745.
   PubMed Web of Science ®Google Scholar
• Dudley, ME, Wunderlich, JR, Shelton, TE, Even, J, Rosenberg, SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 2008;26:332–42. doi:10.1097/00002371-200307000-00005.
   Google Scholar
• Idorn, M, Thor Straten, P, Svane, IM, Met, Ö. Transfection of Tumor-Infiltrating T Cells with mRNA Encoding CXCR2. Methods Mol. Biol. 2016;1428:261–76. doi:10.1007/978-1-4939-3625-0_17. PMID:27236805.
   PubMedGoogle Scholar
• Cameron, BeryAB, Dukes, J, Harper, JV, Kannan, V, Bianchi, FC, Grand, F, Brewer, JE, Gupta, M, Plesa, G, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 2013;5:197ra103. doi:10.1126/scitranslmed.3006034. PMID:23926201.
   PubMed Web of Science ®Google Scholar
• Donia, M, Junker, N, Ellebaek, E, Andersen, MH, Straten, PT, Svane, IM. Characterization and comparison of ‘Standard’ and ‘Young’ tumor infiltrating lymphocytes for adoptive cell therapy at a Danish Translational Research Institution. Scand. J. Immunol. 2011;75:157–67.
   Web of Science ®Google Scholar
• Ji, RR, Chasalow, SD, Wang, L, Hamid, O, Schmidt, H, Cogswell, J, Alaparthy, S, Berman, D, Jure-Kunkel, M, Siemers, NO, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 2012;61:1019–31. doi:10.1007/s00262-011-1172-6. PMID:22146893.
   PubMed Web of Science ®Google Scholar
• Vasaturo, A, Halilovic, A, Bol, KF, Verweij, DI, Blokx, WA, Punt, CJ, Groenen, PJ, van Krieken, JH, Textor, J, de Vries, IJ, et al. T-cell landscape in a primary melanoma predicts the survival of patients with metastatic disease after their treatment with dendritic cell vaccines. Cancer Res. 2016;76:3496–506. doi:10.1158/0008-5472.CAN-15-3211. PMID:27197179.
   PubMed Web of Science ®Google Scholar
• Hamid, O, Schmidt, H, Nissan, A, Ridolfi, L, Aamdal, S, Hansson, J, Guida, M, Hyams, DM, Gómez, H, Bastholt, L, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J. Transl. Med. 2011;9:204. doi:10.1186/1479-5876-9-204. PMID:22123319.
   PubMed Web of Science ®Google Scholar
• Bedognetti, D, Spivey, TL, Zhao, Y, Uccellini, L, Tomei, S, Dudley, ME, Ascierto, ML, De Giorgi V, LQ, Delogu, LG, et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br. J. Cancer. 2013;109:2412–23. doi:10.1038/bjc.2013.557. PMID:24129241.
   PubMed Web of Science ®Google Scholar
• Sapoznik, S, Ortenberg, R, Galore-Haskel, G, Kozlovski, S, Levy, D, Avivi, C, Barshack, I, Cohen, CJ, Besser, MJ, Schachter, J, et al. CXCR1 as a novel target for directing reactive T cells toward melanoma: Implications for adoptive cell transfer immunotherapy. Cancer Immunol. Immunother. 2012;61:1833–47. doi:10.1007/s00262-012-1245-1. PMID:22441657.
   PubMed Web of Science ®Google Scholar
• Mikucki, ME, Fisher, DT, Matsuzaki, J, Skitzki, JJ, Gaulin, NB, Muhitch, JB, Ku, AW, Frelinger, JG, Odunsi, K, Gajewski, TF, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat. Commun. 2015;6:7458. doi:10.1038/ncomms8458. PMID:26109379.
   PubMed Web of Science ®Google Scholar
• Mikucki, ME, Skitzki, JJ, Frelinger, JG, Odunsi, K, Gajewski, TF, Luster, AD, Evans, SS. Unlocking Tumor Vascular Barriers with CXCR3: Implications for Cancer Immunotherapy. Oncoimmunology. 2016;5:00–00. doi:10.1080/2162402X.2015.1116675.
   Web of Science ®Google Scholar
• Viola, A, Sarukhan, A, Bronte, V, Molon, B. The pros and cons of chemokines in tumor immunology. Trends Immunol. 2012;33:496–504. doi:10.1016/j.it.2012.05.007. PMID:22726608.
   PubMed Web of Science ®Google Scholar
• Kershaw, MH, Wang, G, Westwood, JA, Pachynski, RK, Tiffany, HL, Marincola, FM, Wang, E, Young, HA, Murphy, PM, Hwu, P. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther. 2002;13:1971–80. doi:10.1089/10430340260355374. PMID:12427307.
   PubMed Web of Science ®Google Scholar
• Peng, W, Ye, Y, Rabinovich, BA, Liu, C, Lou, Y, Zhang, M, Whittington, M, Yang, Y, Overwijk, WW, Lizée, G, et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin. Cancer Res. 2010;16:5458–68. doi:10.1158/1078-0432.CCR-10-0712. PMID:20889916.
   PubMed Web of Science ®Google Scholar
• Sackstein, R, Schatton, T, Barthel, SR. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. Lab Investig. 2017;97:669–97. doi:10.1038/labinvest.2017.25. PMID:28346400.
   PubMedGoogle Scholar
• Rongvaux, A, Takizawa, H, Strowig, T, Willinger, T, Eynon, EE, Flavell, RA, Manz, MG. Human hemato-lymphoid system mice: Current use and future potential for medicine. Annual review of immunology. 2013;37:635–74. doi:10.1146/annurev-immunol-032712-095921. PMID:23330956.
   PubMedGoogle Scholar
• Martinet, L, Le Guellec, S, Filleron, T, Lamant, L, Meyer, N, Rochaix, P, Garrido, I, Girard, JP. High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes. Oncoimmunology. 2012;1:829–39. doi:10.4161/onci.20492. PMID:23162750.
   PubMed Web of Science ®Google Scholar
• Brehm, MA, Shultz, LD, Luban, J, Greiner, DL. Overcoming current limitations in humanized mouse research. J. Infect. Dis. 2013;208(Suppl):S125–30. doi:10.1093/infdis/jit319. PMID:24151318.
   PubMedGoogle Scholar
• Moon, EK, Carpenito, C, Sun, J, Wang, LC, Kapoor, V, Predina, J, Powell, DJ Jr, Riley, JL, June, CH, Albelda, SM. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 2011;17:4719–30. doi:10.1158/1078-0432.CCR-11-0351. PMID:21610146.
   PubMed Web of Science ®Google Scholar
• Wennerberg, E, Kremer, V, Childs, R, Lundqvist, A. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. Cancer Immunol. Immunother. 2014;64:225–35. doi:10.1007/s00262-014-1629-5. PMID:25344904.
   PubMed Web of Science ®Google Scholar
• Thor Straten, P, Kirkin, AF, Seremet, T, Zeuthen, J. Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines. Int J cancer. 1997;70:582–6. doi:10.1002/(SICI)1097-0215(19970304)70:5%3c582::AID-IJC15%3e3.0.CO;2-F. PMID:9052759.
   PubMed Web of Science ®Google Scholar